Skip to main content
. 2011 Jul 29;301(4):H1559–H1569. doi: 10.1152/ajpheart.00262.2011

Fig. 2.

Fig. 2.

Representative tracing (A and B) and group data (C) showing the sympathoexcitatory responses to ICV PGE2 were significantly diminished by ICV pretreatment with EP3 receptor antagonist L-798106 (10 nmol) but not affected by ICV pretreatment with the EP4 receptor antagonist L-161982 (10 nmol) or the EP1 receptor antagonist SC-19220 (10 nmol). Arrows indicate time of PGE2 injections. n, Number of interventions. *P < 0.05 vs. Veh; †P < 0.05 vs. Veh + PGE2.

HHS Vulnerability Disclosure